R. Park

Plasma proteomic biomarkers identify non-responders and reveal biological insights about the tumor microenvironment in melanoma patients after PD1 blockade

N. Hacohen, R. Sullivan, K. Flaherty, 2022, bioRxiv.

Sequential pembrolizumab cooperates with platinum/5FU to remodel the tumor microenvironment in advanced gastric cancer: a phase II chemoimmunotherapy trial

R. Cristescu, T. Kim, M. Strickland, 2023, medRxiv.

A genome-wide CRISPR screen identifies a restricted set of HIV host dependency factors

Nir Hacohen, Nevan J Krogan, David M Sabatini, 2016, Nature Genetics.

150 Circulatory plasma proteomic biomarkers predict response to immunotherapy in melanoma patients and reveal biological insights into the tumor microenvironment

N. Hacohen, K. Flaherty, Dennie T. Frederick, 2022, Regular and Young Investigator Award Abstracts.

Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses

Gaurav D. Gaiha, B. Walker, E. Rossin, 2021, Cell.

Endoplasmic reticulum chaperone GRP78/BiP is critical for mutant Kras-driven lung tumorigenesis

Amy S. Lee, L. Dubeau, D. Mullen, 2021, Oncogene.

HLA class-I-peptide stability mediates CD8+ T cell immunodominance hierarchies and facilitates HLA-associated immune control of HIV

Gaurav D. Gaiha, B. Walker, E. Rossin, 2021, Cell reports.

Early immune remodeling steers clinical response to frontline chemoimmunotherapy in advanced gastric cancer.

Jeeyun Lee, Y. Heo, Seung-Tae Kim, 2024, Cancer discovery.

Characterization of cell states in biliary tract cancers identifies mechanisms of therapeutic resistance in a phase II trial of DKN-01/nivolumab

N. Hacohen, M. Kagey, P. Enzinger, 2024, medRxiv.